Aegerion Pharmaceuticals Inc

Most Recent

  • Consumer

    Point72 Asset Management opens new position in Pier 1 Imports

    E-commerce represented approximately 1% of total sales in fiscal 2013, 4% in fiscal year 2014, 9% in the first quarter of fiscal 2015, and 9.7% in the second quarter of fiscal 2015.

    By Samantha Nielson
  • uploads///LL

    Point72 Asset Management raises stake in Lumber Liquidators

    The company “saw improvement in net sales trends over the course of the quarter as inventory levels recovered and the fall flooring season began.” But the shares are down 49% in the year to date.

    By Samantha Nielson
  • uploads///Cymabay

    Point72 Asset Management takes position in CymaBay Therapeutics

    CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.

    By Samantha Nielson
  • uploads///AGTC

    Point72 Asset Management adds position in Applied Genetic Tech

    Using the company’s partnerships and experience in ophthalmology, it plans to expand into a disease indication with a larger market. The company says it expects to place a new product candidate for this large market opportunity into development some time in 2015.

    By Samantha Nielson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Small-Caps Are Topping the IBB Portfolio

    Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.

    By Peter Neil
  • uploads///AZN
    Fund Managers

    AQR Capital sold its position in AstraZeneca

    AstraZeneca is one of a few pure-play bio-pharmaceutical companies that span a medicine’s entire value chain.

    By Diana Key
  • uploads///KND
    Basic Materials

    Point72 Asset Management ups position in Kindred Healthcare

    The new company will be the largest and most geographically diversified home-health and hospice organization in the United States. It’s expected to generate pro forma annual revenues of approximately $7.1 billion.

    By Samantha Nielson
  • uploads///KRA
    Basic Materials

    Point72 Asset Management adds to position in Kraton Polymers

    Kraton is a leading global producer of engineered polymers and one of the world’s largest producers of styrenic block copolymers. The company reported sales revenue of $323.8 million in the second quarter.

    By Samantha Nielson
  • uploads///AMC
    Basic Materials

    Point72 Asset Management increases position in AMC Entertainment

    The additional capital will support AMC’s strategic focus on more guest comfort and convenience, enhanced food and beverage, and premium sight and sound.

    By Samantha Nielson
  • uploads///INSM

    Point72 Asset Management raises position in Insmed

    “If approved for NTM patients, we believe Arikayce would be the first and only approved inhaled antibiotic for the treatment of NTM lung infections.” – Insmed

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.